Lataa...
Cyclophosphamide–bortezomib–dexamethasone compared with bortezomib–dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
INTRODUCTION: Cyclophosphamide–bortezomib–dexamethasone (CyBorD) is considered a standard induction regimen for transplant-eligible patients with newly diagnosed multiple myeloma (mm). It has not been prospectively compared with bortezomib–dexamethasone (Bor-Dex). We aimed to compare the efficacy of...
Tallennettuna:
| Julkaisussa: | Curr Oncol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Multimed Inc.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7253752/ https://ncbi.nlm.nih.gov/pubmed/32489256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.5385 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|